MATUCCI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.833
NA - Nord America 1.817
AS - Asia 423
AF - Africa 1
Totale 4.074
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.815
PL - Polonia 795
RU - Federazione Russa 320
IT - Italia 289
IE - Irlanda 169
SE - Svezia 145
SG - Singapore 111
HK - Hong Kong 103
CN - Cina 95
JO - Giordania 45
GB - Regno Unito 38
IN - India 34
VN - Vietnam 26
CH - Svizzera 24
FI - Finlandia 21
BE - Belgio 10
DE - Germania 8
FR - Francia 5
UA - Ucraina 4
RO - Romania 3
CA - Canada 2
ID - Indonesia 2
IR - Iran 2
KR - Corea 2
PH - Filippine 2
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
TR - Turchia 1
Totale 4.074
Salva come PNG Salva come JPEG
Città #
Warsaw 794
Fairfield 278
Chandler 181
Dublin 169
Ashburn 156
Woodbridge 107
Seattle 106
Wilmington 106
Houston 105
Cambridge 103
Singapore 96
Ann Arbor 93
Hong Kong 66
Altamura 63
Lawrence 63
Florence 50
Princeton 40
Moscow 39
Buffalo 32
Shanghai 32
Beijing 31
Mumbai 25
Boston 24
Dong Ket 24
New York 22
Kent 21
Medford 20
San Diego 20
Bern 18
Luni 18
Santa Clara 14
Los Angeles 13
Boardman 11
Milan 11
Brussels 10
Norwalk 8
Rome 8
Helsinki 7
Liverpool 7
Livorno 7
London 7
Phoenix 7
Naples 6
Redwood City 6
Andover 5
Jacksonville 5
Castelliri 4
Hillsboro 4
Redmond 4
Busto Arsizio 3
Calenzano 3
Campi Bisenzio 3
Caulonia 3
Chicago 3
Lappeenranta 3
Peschiera 3
Washington 3
Acton 2
Bengaluru 2
Bologna 2
Canosa di Puglia 2
Craiova 2
Falls Church 2
Frankfurt am Main 2
Lambeth 2
Latina 2
Laurel 2
Leawood 2
Milzano 2
Monopoli 2
Nanchang 2
Nerviano 2
Nola 2
Palermo 2
Parma 2
Pune 2
Romainville 2
Salerno 2
Sant'Agata Bolognese 2
Seoul 2
Sommacampagna 2
Toronto 2
Varese 2
Wuhan 2
Zurich 2
Arnsberg 1
Bari 1
Birkenhead 1
Bucharest 1
Cedar Knolls 1
Central 1
Chongqing 1
Cologne 1
Duncan 1
Fontebuona 1
Genoa 1
Grafing 1
Guangzhou 1
Hanover 1
Hefei 1
Totale 3.141
Salva come PNG Salva come JPEG
Nome #
Hapten-Specific TH17 Cells in the Peripheral Blood of β-Lactam-Induced AGEP. 240
Immunoglobulin replacement therapy for yellow nail syndrome 218
The in vitro amplification of β-lactam-specific memory t cells improves the diagnostic performance of IGE detection and lymphocyte transformation test 185
High serum β-lactams specific/total IgE ratio is associated with immediate reactions to β-lactams antibiotics 147
Concomitant Bilastine and Montelukast as Additive Therapy for Seasonal Allergic Rhinoconjunctivits and Mild-to-Moderate Asthma. The SKY Study 144
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies 144
Efficacy and safety of mepolizumab (Anti-Interleukin-5) treatment in Gleich's syndrome 137
Biweekly hizentra® in primary immunodeficiency: A multicenter, observational cohort study (IBIS) 131
Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. 130
Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study 120
Autoimmune hepatitis in a patient affected by neuromyelitis optica: A new association. 115
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study 113
Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab 108
Malattia di Anderson-Fabry 108
Assays and strategies for immunogenicity assessment of biological agents. 106
Miescher's cheilitis: Surgical management and long term outcome of an extremely severe case. 103
Corrigendum to "Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia" [Int. Immunopharmacol. 44 (2017) 38-42] 99
The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019) 94
Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. 91
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 90
Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI 87
The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment 85
Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab 85
Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia. 82
Subcutaneous Immunoglobulin Twenty Percent Every Two Weeks in Pediatric Patients with Primary Immunodeficiencies: Subcohort Analysis of the IBIS Study 82
High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients 70
Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19 69
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 65
Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis 63
Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity 61
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 58
Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. 53
Early experience of an infectious and tropical diseases unit during the coronavirus disease (COVID-19) pandemic, Florence, Italy, February to March 2020 52
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 49
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 49
Effectiveness of low-dose intravenous immunoglobulin therapy in minor primary antibody deficiencies: a two-year real-life experience 47
Effectiveness of Tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real life study 44
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer 41
Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma 40
Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab 37
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 37
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 33
Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis 29
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 27
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 27
Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience 26
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 22
Primary antibody deficiencies represent an underestimated comorbidity in asthma patients: efficacy of immunoglobulin replacement therapy in asthma control 17
Baseline Eosinophil Count as a Potential Clinical Biomarker for Clinical Complexity in EGPA: A Real-Life Experience 16
Case Report: A child with NFKB1 haploinsufficiency explaining the linkage between immunodeficiency and short stature 15
EGPA Phenotyping: Not Only ANCA, but Also Eosinophils 14
null 12
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 11
Mechanisms of Action of Ig Preparations: Immunomodulatory and Anti-Inflammatory Effects 11
Totale 4.139
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.773
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.773
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020693 0 0 24 59 105 88 84 100 84 63 75 11
2020/2021637 52 60 6 87 41 69 42 38 74 91 34 43
2021/2022305 5 11 18 11 11 29 18 34 16 24 50 78
2022/2023878 66 189 50 43 52 143 113 50 96 15 32 29
2023/2024534 11 31 62 30 50 61 37 101 14 44 59 34
2024/2025502 96 289 117 0 0 0 0 0 0 0 0 0
Totale 4.139